TRIM66 (tripartite motif containing 66) functions as an oncogene that promotes malignant progression across multiple cancer types. The protein is consistently overexpressed in non-small cell lung cancer (NSCLC), prostate cancer, glioma, colorectal cancer, hepatocellular carcinoma, and osteosarcoma, where high expression correlates with poor prognosis and metastasis 123456. Mechanistically, TRIM66 promotes cancer cell proliferation, migration, invasion, and epithelial-mesenchymal transition (EMT) while inhibiting apoptosis 145. The protein exerts its oncogenic effects through multiple pathways including TGF-β/SMAD signaling via MMP9 interaction 17, JAK2/STAT3 pathway activation 24, and glucose metabolism regulation through cMyc/GLUT3 signaling 3. TRIM66 also functions in a competing endogenous RNA network, being regulated by circSATB2/miR-150-5p axis 8. Clinically, TRIM66 represents a promising therapeutic target, as its knockdown consistently inhibits tumor growth and metastasis in various cancer models, making it a potential prognostic biomarker and drug target for cancer treatment 643.